晨光生物(300138.SZ)2021年度淨利潤預增20.27%-38.94%
格隆匯1月24日丨晨光生物(300138.SZ)公佈，預計2021年度歸屬於上市公司股東的淨利潤3.22億元-3.72億元，同比增長20.27%-38.94%；歸屬於上市公司股東扣除非經常性損益後的淨利潤2.67億元-3.17億元，同比增長18.40%-40.58%。
2021年，公司堅持以客户為中心，持續強化技術、生產和管理優勢，產品競爭力持續提升。主導產品辣椒紅銷量8000多噸，同比增長約12%，領先優勢進一步擴大；辣椒精產品搶抓市場機遇，產品銷量1100多噸，銷售收入再創新高；葉黃素產品銷量近3億克，保持世界領先。在保證產品銷量的同時，更多的技術人員協同業務人員深入市場一線，幫助客户解決產品應用痛點、難點問題，得到了客户的高度認可，鞏固了在行業內的主導地位。
營養藥用類產品市場開發取得新成績，水飛薊素、食品級葉黃素、葡萄籽提取物等產品銷售與斯維詩、納世凱爾、修正藥業等知名終端客户達成戰略合作。番茄紅素應用開發取得新進展，同比增長50%以上；迷迭香提取物、水飛薊素、薑黃素等產品銷售勢頭持續向好，正在成為新的利潤增長點；香辛料產品銷售收入超過1.1億元，花椒提取物、生薑提取物、孜然提取物等產品銷量均實現大幅增長，進一步提升了市場佔有率；甜菊糖產品全年銷售收入近2億元，實現新的突破；保健食品業務不斷拓展市場，實現翻番；動保類產品發展勢頭旺盛，正在成為公司效益增長的新亮點；棉籽蛋白業務不斷加強對行情的分析把控，堅持對鎖經營模式，有效規避了行情波動帶來的風險。
公司原料基地建設有序推進，新疆和雲南發展萬壽菊種植15萬畝；印度子公司面對嚴峻的疫情形勢和諸多困難，發展萬壽菊種植面積3.1萬多畝，較2020年增長超過一倍；贊比亞農業公司錫納宗圭農場發展辣椒種植3萬畝，已經實現盈利；奇蓬勃農場土地開發快速推進，萬壽菊種植開發面積近1萬畝，正在打造原料基地的戰略優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
